 BOSTON, Jan. 04, 2023 GLOBE NEWSWIRE -- HilleVax, Inc. Nasdaq: HLVX, a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023, at 4:30 p.m. EST 1:30 p.m. PST. HIL-214, HilleVaxs investigational virus-like particle VLP based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. 